What can we help you find?
The prevalence of HIV in jails and prisons is approximately 4 times higher than that of the general United States population.
Researchers at the National Institutes of Health (NIH) have found that the antiretroviral drugs, dolutegravir and emtricitabine/tenofovir alafenamide fumurate (DTG+FTC/TAF), may comprise the safest and most effective HIV treatment regimen currently available during pregnancy.
Recent estimates indicate that less than 10% of patients who are at risk for acquiring HIV are prescribed PrEP.
Levels of the HIV pre-exposure prophylaxis (PrEP) drug tenofovir among African adolescent girls and young women were more than 30% lower in those who were pregnant than in those who had recently given birth.
Only 15% of those at risk are currently using PrEP.
A 72-week interim analysis of observational data from the ongoing SEARCH study was used to examine optimal strategies for PrEP engagement and uptake after population-level HIV testing and universal PrEP access.
Top news from across the health care landscape.
Scientists at the Gladstone Institutes have cataloged host proteins that physically bind to HIV proteins, which identify human proteins that the virus can use to infect cells and spread.
The bill is intended to "prevent a health insurance carrier from requiring a covered person to undergo step therapy or to receive prior authorization before receiving HIV infection prevention drugs."
The Undectectable = Untransmittable (U=U) campaign started in early 2016 and has been sharing the message to dismantle the stigma surrounding HIV ever since. More than 970 community partners from 101 countries have come together to clear up the confusion about the science behind U=U.
Research conducted by the National Institute of Minority Health and Health Disparities has found that less than 1 in 4 adolescent men who have sex with men (AMSM) ever get tested for HIV.
The study, called DELIVER: A Phase 3b Safety Study of the Dapivirine Ring and PrEP in Pregnant Women, will complement an ongoing NIH-funded trial of PrEP in adolescents and young women during pregnancy and the first 6 months after birth.